1019 related articles for article (PubMed ID: 17445086)
1. Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease.
Boerrigter G; Burnett JC
Cardiovasc Drug Rev; 2007; 25(1):30-45. PubMed ID: 17445086
[TBL] [Abstract][Full Text] [Related]
2. Soluble guanylate cyclase stimulators in pulmonary hypertension.
Stasch JP; Evgenov OV
Handb Exp Pharmacol; 2013; 218():279-313. PubMed ID: 24092345
[TBL] [Abstract][Full Text] [Related]
3. Preconditioning with soluble guanylate cyclase activation prevents postischemic inflammation and reduces nitrate tolerance in heme oxygenase-1 knockout mice.
Wang WZ; Jones AW; Wang M; Durante W; Korthuis RJ
Am J Physiol Heart Circ Physiol; 2013 Aug; 305(4):H521-32. PubMed ID: 23771693
[TBL] [Abstract][Full Text] [Related]
4. Soluble guanylate cyclase: a new therapeutic target for pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Dasgupta A; Bowman L; D'Arsigny CL; Archer SL
Clin Pharmacol Ther; 2015 Jan; 97(1):88-102. PubMed ID: 25670386
[TBL] [Abstract][Full Text] [Related]
5. NO-independent, haem-dependent soluble guanylate cyclase stimulators.
Stasch JP; Hobbs AJ
Handb Exp Pharmacol; 2009; (191):277-308. PubMed ID: 19089334
[TBL] [Abstract][Full Text] [Related]
6. Activation of haem-oxidized soluble guanylyl cyclase with BAY 60-2770 in human platelets lead to overstimulation of the cyclic GMP signaling pathway.
Mendes-Silverio CB; Leiria LO; Morganti RP; Anhê GF; Marcondes S; Mónica FZ; De Nucci G; Antunes E
PLoS One; 2012; 7(11):e47223. PubMed ID: 23144808
[TBL] [Abstract][Full Text] [Related]
7. Reduced vascular responses to soluble guanylyl cyclase but increased sensitivity to sildenafil in female rats with type 2 diabetes.
Goulopoulou S; Hannan JL; Matsumoto T; Ogbi S; Ergul A; Webb RC
Am J Physiol Heart Circ Physiol; 2015 Jul; 309(2):H297-304. PubMed ID: 25957216
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet properties of a novel, non-NO-based soluble guanylate cyclase activator, BAY 41-2272.
Hobbs AJ; Moncada S
Vascul Pharmacol; 2003 Oct; 40(3):149-54. PubMed ID: 13678646
[TBL] [Abstract][Full Text] [Related]
9. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation.
Evgenov OV; Kohane DS; Bloch KD; Stasch JP; Volpato GP; Bellas E; Evgenov NV; Buys ES; Gnoth MJ; Graveline AR; Liu R; Hess DR; Langer R; Zapol WM
Am J Respir Crit Care Med; 2007 Dec; 176(11):1138-45. PubMed ID: 17872487
[TBL] [Abstract][Full Text] [Related]
10. Activators and stimulators of soluble guanylate cyclase counteract myofibroblast differentiation of prostatic and dermal stromal cells.
Zenzmaier C; Kern J; Heitz M; Plas E; Zwerschke W; Mattesich M; Sandner P; Berger P
Exp Cell Res; 2015 Nov; 338(2):162-9. PubMed ID: 26410556
[TBL] [Abstract][Full Text] [Related]
11. NO-independent stimulation or activation of soluble guanylyl cyclase during early reperfusion limits infarct size.
Bice JS; Keim Y; Stasch JP; Baxter GF
Cardiovasc Res; 2014 Feb; 101(2):220-8. PubMed ID: 24259501
[TBL] [Abstract][Full Text] [Related]
12. NO- and haem-independent soluble guanylate cyclase activators.
Schmidt HH; Schmidt PM; Stasch JP
Handb Exp Pharmacol; 2009; (191):309-39. PubMed ID: 19089335
[TBL] [Abstract][Full Text] [Related]
13. Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure.
Boerrigter G; Costello-Boerrigter LC; Cataliotti A; Lapp H; Stasch JP; Burnett JC
Hypertension; 2007 May; 49(5):1128-33. PubMed ID: 17325237
[TBL] [Abstract][Full Text] [Related]
14. Soluble guanylate cyclase activator reverses acute pulmonary hypertension and augments the pulmonary vasodilator response to inhaled nitric oxide in awake lambs.
Evgenov OV; Ichinose F; Evgenov NV; Gnoth MJ; Falkowski GE; Chang Y; Bloch KD; Zapol WM
Circulation; 2004 Oct; 110(15):2253-9. PubMed ID: 15466650
[TBL] [Abstract][Full Text] [Related]
15. Cinaciguat, a soluble guanylate cyclase activator for the potential treatment of acute heart failure.
Tamargo J; Duarte J; Caballero R; Delpón E
Curr Opin Investig Drugs; 2010 Sep; 11(9):1039-47. PubMed ID: 20730699
[TBL] [Abstract][Full Text] [Related]
16. Riociguat for the treatment of pulmonary hypertension.
Hambly N; Granton J
Expert Rev Respir Med; 2015; 9(6):679-95. PubMed ID: 26599488
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of relaxant activity of the nitric oxide-independent soluble guanylyl cyclase stimulator BAY 41-2272 in rat tracheal smooth muscle.
Toque HA; Mónica FZ; Morganti RP; De Nucci G; Antunes E
Eur J Pharmacol; 2010 Oct; 645(1-3):158-64. PubMed ID: 20670622
[TBL] [Abstract][Full Text] [Related]
18. The chemistry and biology of soluble guanylate cyclase stimulators and activators.
Follmann M; Griebenow N; Hahn MG; Hartung I; Mais FJ; Mittendorf J; Schäfer M; Schirok H; Stasch JP; Stoll F; Straub A
Angew Chem Int Ed Engl; 2013 Sep; 52(36):9442-62. PubMed ID: 23963798
[TBL] [Abstract][Full Text] [Related]
19. Soluble guanylyl cyclase (sGC) degradation and impairment of nitric oxide-mediated responses in urethra from obese mice: reversal by the sGC activator BAY 60-2770.
Alexandre EC; Leiria LO; Silva FH; Mendes-Silvério CB; Calmasini FB; Davel AP; Mónica FZ; De Nucci G; Antunes E
J Pharmacol Exp Ther; 2014 Apr; 349(1):2-9. PubMed ID: 24421320
[TBL] [Abstract][Full Text] [Related]
20. The fibrate gemfibrozil is a NO- and haem-independent activator of soluble guanylyl cyclase: in vitro studies.
Sharina IG; Sobolevsky M; Papakyriakou A; Rukoyatkina N; Spyroulias GA; Gambaryan S; Martin E
Br J Pharmacol; 2015 May; 172(9):2316-29. PubMed ID: 25536881
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
